Brad is a founding general partner of Strategic Healthcare Investment Partners. The investment focus is:
He currently serves on a number of private company boards and one public board, Nevro, where he was an investor prior to the IPO. Brad led JJDC investments in a number of companies that were ultimately acquired by JNJ, including Biosense, Atrionix, and Indigo Medical.
Brad was Head of Johnson & Johnson Development Corporation (JJDC) from 2011 to 2015. JJDC is Johnson & Johnson’s venture investing arm and has investors based in Si-Valley, Boston, Shanghai, London and Tel Aviv. He established JJDC’s west coast office in 1997 and was an investor in medical devices, healthtech, and biotech for JNJ from 1992-2011.
Prior to JJDC, Brad worked in preclinical surgery and product development at Ethicon, JNJ’s wound closure company, in projects to develop lasers, blood compatible polymers, wound healing stimulation, internal and external stapling and suture materials. Prior to joining JJDC he was in JNJ’s Corporate Office of Science and Technology focused on next generation procedures and biomaterials for medical device applications.
Dr. Vale received a PhD in Biomedical Engineering from Iowa State University on the development of blood compatible polymers and a Doctor of Veterinary Medicine from Washington State University.